Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 162 entries
View as:

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04974047 Org: User:
Start: 08/17/21 End: 10/25/24 Due: 10/25/25

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04472650 Org: User:
Start: 07/23/20 End: 11/09/20 Due: 11/09/21

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04551898 Org: User:
Start: 12/02/20 End: 05/25/21 Due: 05/25/22

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03427814 Org: User:
Start: 07/03/18 End: 01/03/23 Due: 01/03/24

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03846427 Org: User:
Start: 02/19/19 End: 05/04/22 Due: 05/04/23

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT02361723 Org: User:
Start: 07/03/14 End: 09/03/19 Due: 09/03/20

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03332017 Org: User:
Start: 11/14/17 End: 12/27/24 Due: 12/27/25

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04005716 Org: User:
Start: 07/22/19 End: 12/29/23 Due: 12/29/24

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

Phase: N/A Priority: Normal
NCT ID: NCT03924986 Org: User:
Start: 03/27/19 End: 12/08/23 Due: 12/08/24

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Phase: N/A Priority: Normal
NCT ID: NCT03336333 Org: User:
Start: 10/31/17 End: 09/30/26 Due: 09/30/27

Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04163523 Org: User:
Start: 05/25/16 End: 07/21/16 Due: 07/21/17

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT04643470 Org: User:
Start: 12/22/20 End: 08/26/24 Due: 08/26/25

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03734016 Org: User:
Start: 11/01/18 End: 02/28/24 Due: 02/28/25

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03145064 Org: User:
Start: 06/30/17 End: 09/03/20 Due: 09/03/21

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02569476 Org: User:
Start: 01/13/16 End: 09/02/20 Due: 09/02/21

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT03493451 Org: User:
Start: 04/13/18 End: 04/21/21 Due: 04/21/22

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03941873 Org: User:
Start: 02/28/19 End: 03/31/23 Due: 03/31/24

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04551963 Org: User:
Start: 11/15/20 End: 02/21/22 Due: 02/21/23

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Phase: N/A Priority: Normal
NCT ID: NCT03332173 Org: User:
Start: 08/31/17 End: 01/11/21 Due: 01/11/22

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03994211 Org: User:
Start: 05/29/19 End: 08/06/21 Due: 08/06/22

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Phase: N/A Priority: Normal
NCT ID: NCT06585488 Org: User:
Start: 11/26/24 End: 12/31/26 Due: 12/31/27

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Phase: N/A Priority: Normal
NCT ID: NCT03419897 Org: User:
Start: 04/09/18 End: 07/06/22 Due: 07/06/23

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Phase: N/A Priority: Normal
NCT ID: NCT03520920 Org: User:
Start: 01/04/18 End: 08/28/20 Due: 08/28/21

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03594747 Org: User:
Start: 07/30/18 End: 04/28/23 Due: 04/28/24

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04277637 Org: User:
Start: 03/24/20 End: 08/30/27 Due: 08/30/28